Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Convalescent Plasma Therapy in Patients With COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Recipient Inclusion Criteria:~- Patients with severe COVID-19 will be considered for randomization and will be transfused convalescent plasma within 3 days of symptom onset (Severe COVID-19) Severe COVID -19 defined by WHO Interim Guidance and the Guideline of Diagnosis and Treatment of COVID-19 of National Health Commission of China (version 5.0) along with confirmation by real-time RT-PCR assay with severe disease i.e. meeting any 2 of the following criteria-~* Patients on ventilator (in last 24 hours)~* Respiratory distress, RR ≥30 beats/min~* Oxygen saturation level less than 90 % in resting state~* Partial pressure of oxygen (PaO2)/oxygen concentration (FiO2) ≤ 300 mmHg~* Lung infiltrates \> 50% within 24 to 48 hours~Recipient Exclusion Criteria:~* Patient/ family members who do not give consent to participate in the study.~* Patients with age less than 18 years~* Patients presenting with multi-organ failure~* Pregnancy~* Individuals with HIV and Viral Hepatitis and Cancer~* Extremely moribund patients with an expected life expectancy of less than 24 hours~* Hemodynamic instability requiring vasopressors~* Previous history of allergy to plasma~* Cirrhosis~* Severe renal impairment with GFR\< 30ml/min or recipients of RRT, peritoneal dialysis~* Patients with uncontrolled diabetes mellitus, hypertension, arrhythmias and unstable Angina~Donor Inclusion Criteria for Plasmapheresis~* Virologically documented (PCR positive by nasopharyngeal swab) who is recovered and free of symptoms for 14 days.~* Has tested negative for SARS CoV 2 on two consecutive tests 24 hrs apart.~* Fulfill all criteria of donor eligibility for donor Plasmapheresis under the Drugs \& Cosmetics Act 1940 and Rules 1945, amended 11.03.2020~* Females who have been pregnant may be tested for anti-HLA antibodies and eligible if negative for the same.~Donors Exclusion Criteria:~* Do not fulfill all criteria of donor eligibility for donor Plasmapheresis under~* the Drugs \& Cosmetics Act 1940 and Rules 1945, amended 11.03.2020~* Females who have been pregnant and have not been tested for HLA antibodies or are HLA antibody positive if tested and previously transfused donors (to prevent TRALI)~* Donors who have taken steroids during treatment for COVID-19

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Convalescent Plasma with Standard of Care (Type: EXPERIMENTAL): Two doses of 250 ml Convalescent plasma from recovered COVID-19 patients + Standard of Care will be given to severely sick COVID-19 patients in the treatment arm
- Standard of Care (Type: ACTIVE_COMPARATOR): The Ministry of Health and Family Welfare has issued detailed guidelines for the management of sCOVID-19 based on varying grades of severity which may be periodically updated. For the management of ARDS or sepsis the respective guidelines issued by ARDSNet and Surviving Sepsis campaign will be followed. Other institutional protocols for supportive management will be implemented. (Ref: Guidelines on Clinical Management of COVID-19. MoHFW, GoI.2020.)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete